194 related articles for article (PubMed ID: 23073207)
21. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
22. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
Wood J; Sames L; Moore A; Ekins S
Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
[TBL] [Abstract][Full Text] [Related]
23. Rare lung disease and orphan drug development.
Spagnolo P; du Bois RM; Cottin V
Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
[TBL] [Abstract][Full Text] [Related]
24. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
25. Translation of rare disease research into orphan drug development: disease matters.
Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
[TBL] [Abstract][Full Text] [Related]
26. Neuromuscular disorders: orphan diseases deserve attention.
de Visser M
Lancet Neurol; 2006 Jan; 5(1):13-4. PubMed ID: 16361013
[No Abstract] [Full Text] [Related]
27. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
28. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
29. A new toolkit for conducting clinical trials in rare disorders.
Abrahamyan L; Diamond IR; Johnson SR; Feldman BM
J Popul Ther Clin Pharmacol; 2014; 21(1):e66-78. PubMed ID: 24671886
[TBL] [Abstract][Full Text] [Related]
30. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
31. Orphan Drugs and Their Impact on Pharmaceutical Development.
Attwood MM; Rask-Andersen M; Schiöth HB
Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
[TBL] [Abstract][Full Text] [Related]
32. Challenges and Opportunities in Rare Disease Drug Development.
Smith BP
Clin Pharmacol Ther; 2016 Oct; 100(4):312-4. PubMed ID: 27612019
[TBL] [Abstract][Full Text] [Related]
33. The routes to orphan drug designation--our recent experience at the FDA.
Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
[No Abstract] [Full Text] [Related]
34. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
35. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
36. Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
Di Paolo A; Arrigoni E
Drugs; 2018 Mar; 78(4):399-410. PubMed ID: 29464665
[TBL] [Abstract][Full Text] [Related]
37. Orphan drugs: Indian perspective.
Kumar H; Sarma P; Medhi B
Indian J Pharmacol; 2017; 49(4):267-269. PubMed ID: 29326485
[No Abstract] [Full Text] [Related]
38. Orphan drug development in China: progress and challenges.
Zhang S; Chen L; Zhang Z; Zhao Y
Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
[No Abstract] [Full Text] [Related]
39. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
40. Financing drug discovery for orphan diseases.
Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
